160 related articles for article (PubMed ID: 34083798)
1. Scaling the immune incline in PDAC.
Rojas LA; Balachandran VP
Nat Rev Gastroenterol Hepatol; 2021 Jul; 18(7):453-454. PubMed ID: 34083798
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects.
Nsingwane Z; Candy G; Devar J; Omoshoro-Jones J; Smith M; Nweke E
Mol Biol Rep; 2020 Aug; 47(8):6269-6280. PubMed ID: 32661873
[TBL] [Abstract][Full Text] [Related]
3. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
4. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.
Balachandran VP; Beatty GL; Dougan SK
Gastroenterology; 2019 May; 156(7):2056-2072. PubMed ID: 30660727
[TBL] [Abstract][Full Text] [Related]
5. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889
[TBL] [Abstract][Full Text] [Related]
6. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
Sahin IH; Askan G; Hu ZI; O'Reilly EM
Ann Oncol; 2017 Dec; 28(12):2950-2961. PubMed ID: 28945842
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for pancreatic ductal adenocarcinoma.
Carpenter E; Nelson S; Bednar F; Cho C; Nathan H; Sahai V; di Magliano MP; Frankel TL
J Surg Oncol; 2021 Mar; 123(3):751-759. PubMed ID: 33595893
[TBL] [Abstract][Full Text] [Related]
9. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
10. Current Status of Immunotherapies for Treating Pancreatic Cancer.
Wu AA; Jaffee E; Lee V
Curr Oncol Rep; 2019 May; 21(7):60. PubMed ID: 31101991
[TBL] [Abstract][Full Text] [Related]
11. Overcoming immunosuppressive tumors.
Dorans K
Lab Anim (NY); 2011 May; 40(5):134. PubMed ID: 21508944
[No Abstract] [Full Text] [Related]
12. Neutrophil in the Pancreatic Tumor Microenvironment.
Jin L; Kim HS; Shi J
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439836
[TBL] [Abstract][Full Text] [Related]
13. Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer).
Yoshimura K; Olino K; Edil BH; Schulick RD; Oka M
Surg Today; 2010 May; 40(5):404-10. PubMed ID: 20425541
[TBL] [Abstract][Full Text] [Related]
14. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
[TBL] [Abstract][Full Text] [Related]
15. Circulating Immunological Biomarkers: Prognosis of Pancreatic Cancer Patients Reflected by the Immune System.
van der Sijde F; Mustafa DAM; Vietsch EE; Katsikis PD; van Eijck CHJ
Pancreas; 2021 Aug; 50(7):933-941. PubMed ID: 34643608
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine.
Lupinacci RM; Bachet JB; André T; Duval A; Svrcek M
Surg Oncol; 2019 Mar; 28():121-127. PubMed ID: 30851885
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic.
Fokas E; O'Neill E; Gordon-Weeks A; Mukherjee S; McKenna WG; Muschel RJ
Biochim Biophys Acta; 2015 Jan; 1855(1):61-82. PubMed ID: 25489989
[TBL] [Abstract][Full Text] [Related]
18. Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy.
Bazhin AV; Shevchenko I; Umansky V; Werner J; Karakhanova S
Cancer Immunol Immunother; 2014 Jan; 63(1):59-65. PubMed ID: 24129765
[TBL] [Abstract][Full Text] [Related]
19. Identification, Validation, and Utilization of Immune Cells in Pancreatic Ductal Adenocarcinoma Based on Marker Genes.
de Koning W; Latifi D; Li Y; van Eijck CHJ; Stubbs AP; Mustafa DAM
Front Immunol; 2021; 12():649061. PubMed ID: 33986743
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Immune Microenvironment on the Prognosis of Pancreatic Ductal Adenocarcinoma Based on Multi-Omics Analysis.
Yang B; Zhou M; Wu Y; Ma Y; Tan Q; Yuan W; Ma J
Front Immunol; 2021; 12():769047. PubMed ID: 34777388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
